Psoriasiform Eruption Secondary to PI3K-delta Inhibitor: Expanding the Spectrum of Psoriasiform Paradoxical Reactions?

被引：2
|
作者：
Pesque, David [1 ]
Sanchez-Gonzalez, Blanca [2 ]
Gallardo, Fernando [1 ]
Segura, Sonia [1 ]
Maria Pujol, Ramon [1 ]
机构：
[1] Univ Autonoma Barcelona UAB, Hosp del Mar, Inst Mar Invest Med, Dept Dermatol, Barcelona, Spain
[2] Univ Autonoma Barcelona UAB, Hosp del Mar, Inst Mar Invest Med, Dept Hematol, Barcelona, Spain
来源：
ACTA DERMATO-VENEREOLOGICA | 2021年 / 101卷
关键词：
D O I：
10.2340/00015555-3783
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
[No abstract available]
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Case report on activated PI3K-delta syndrome
    Crisanto-Lopez, Israel E.
    Perez-Arzola, Alan A.
    Hernandez-Castaneda, Yazmin
    Carrasco-Trinidad, Reyna G.
    Vera-Loaiza, Aurea
    Jimenez-Perez, Berenice
    Guzman-Santiago, Tania A.
    Rodriguez-Hurtado, Pablo O.
    Salazar-Bonilla, Wilbert
    Juarez-Melchor, Daniela
    BOLETIN MEDICO DEL HOSPITAL INFANTIL DE MEXICO, 2024, 81 (04): : 245 - 249
  • [2] TGR-1202: A NOVEL PI3K-DELTA SPECIFIC INHIBITOR IN MULTIPLE MYELOMA
    Vakkalanka, S.
    Miskin, H.
    Sportelli, P.
    Viswanadha, S.
    HAEMATOLOGICA, 2013, 98 : 315 - 316
  • [3] The MEK-inhibitor pimasertib is synergistic with PI3K-delta and BTK inhibitors in lymphoma models
    Gaudio, Eugenio
    Tarantelli, Chiara
    Barassi, Chiara
    Bernasconi, Elena
    Kwee, Ivo
    Cascione, Luciano
    Ponzoni, Maurilio
    Rinaldi, Andrea
    Stathis, Anastasios
    Goodstal, Samantha
    Zucca, Emanuele
    Bertoni, Francesco
    CANCER RESEARCH, 2015, 75
  • [4] FUNCTIONAL ROLE OF PI3K-DELTA IN MALIGNANT B CELLS
    Neumann, L.
    Goeckeritz, E.
    Hallek, M.
    Krause, G.
    HAEMATOLOGICA, 2016, 101 : 429 - 429
  • [5] TGR-1202-a novel PI3K-delta inhibitor that differentially regulates the T cells in CLL
    Maharaj, Kamira
    Pinilla-Ibarz, Javier
    Sahakian, Eva
    Powers, John
    Deng, Susan
    Achille, Alex
    PabonSaldana, Mibel
    Miskin, Hari
    Maryanski, Dave
    Fonseca, Renee
    LEUKEMIA & LYMPHOMA, 2017, 58 : 177 - 178
  • [6] Hematopoietic Stem Cell Transplantation for the Patients with Activated PI3K-Delta Syndrome
    Imai, K.
    Tsujita, Y.
    Mitsui-Sekinaka, K.
    Mitsuiki, N.
    Takashima, T.
    Okano, T.
    Aoki, Y.
    Kimoto, F.
    Inoue, M.
    Iwasaki, F.
    Kaneko, T.
    Waragai, T.
    Sano, H.
    Kikuta, A.
    Morio, T.
    Nonoyama, S.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 : S286 - S287
  • [7] SERUM CHEMOKINES AND CYTOKINES IN CLL PATIENTS TREATED WITH DUVELISIB, AN ORAL DUAL INHIBITOR OF PI3K-DELTA, GAMMA
    Douglas, M.
    Allen, K.
    Sweeney, J.
    O'Brien, S.
    Flinn, I.
    Horwitz, S.
    Byrd, J.
    Patel, M.
    Kahl, B.
    Foss, F.
    Porcu, P.
    Kelly, V.
    Stern, H.
    HAEMATOLOGICA, 2015, 100 : 413 - 413
  • [8] Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas
    Gaudio, E.
    Tarantelli, C.
    Kwee, I.
    Barassi, C.
    Bernasconi, E.
    Rinaldi, A.
    Ponzoni, M.
    Cascione, L.
    Targa, A.
    Stathis, A.
    Goodstal, S.
    Zucca, E.
    Bertoni, F.
    ANNALS OF ONCOLOGY, 2016, 27 (06) : 1123 - 1128
  • [9] Endoscopic airway manifestations in a pediatric patient with activated PI3K-delta syndrome
    Williams, Sophia N.
    PEDIATRIC PULMONOLOGY, 2020, 55 (11) : 2836 - 2837
  • [10] Pityriasiform and psoriasiform dermatological toxicities associated with PI3K pathway inhibition in cancer treatment
    Bach, Daniel
    Gupta, Sameer
    Huang, Victor
    LeBoeuf, Nicole
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB173 - AB173
12345